Please login to the form below

Not currently logged in
Email:
Password:

Biomarkers predict rheumatoid drug success

Remission is more likely for RA patients with positive rheumatoid factor or aCCP over seronegative patients after MabThera plus MTX treatment

Rheumatoid arthritis (RA) patients who test positive for the auto-antibodies rheumatoid factor (RF) or anti-cyclic citrullinated peptide (aCCP) are more than twice as likely to achieve remission and are three times more likely to get a significant improvement in symptoms when taking MabThera (rituximab) plus methotrexate (MTX) than those who test negative, according to new research presented at the British Society of Rheumatology (BSR) annual conference.

The research consisted of two phase III studies led by Professor John Isaacs, professor of clinical rheumatology at Newcastle University, and involved eight centres in which patients with active RA who had previously experienced an inadequate response to other disease-modifying anti-rheumatic drugs (DMARDs) were treated with the monoclonal antibody rituximab plus MTX. A total of 670 patients (554 seropositive and 116 seronegative) were pooled and analysed.

At week 48, 44.9 per cent of seropositive patients achieved a 50 per cent reduction in the signs and symptoms of RA, compared with the 22.8 per cent of seronegative patients who achieved the same degree of improvement.

Professor John Isaacs commented: "By identifying in advance which groups are most likely to respond to, or to have an enhanced response to, drugs like rituximab, we can ensure they are treated early enough to prevent irreversible joint damage and disability. Additionally this will reduce treatment costs by avoiding the use of ineffective drugs."

This constitutes the first time research into the treatment of RA has been able to identify biomarkers to pinpoint which patients would respond better to any specific treatment. Approximately 80 per cent of patients with RA are seropositive for one of these auto-antibodies. The economic burden of RA is currently estimated at almost £8bn annually.

21st April 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics